 "Is the famous weight-loss drug coming to India soon? What we know so far")
Obesity, which is linked to noncommunicable diseases such as diabetes, cardiovascular disease, and hypertension, has long been a global concern. And Indians are no strangers to it.
To address the problem, Eli Lilly, a US drugmaker, plans to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year after clearing an ongoing regulatory review, CEO David Ricks told Reuters on Wednesday.
Trizepatide, marketed in the United States under the names Mounjaro for diabetes and Zepbound for weight loss, has received attention for its efficacy in both disease management and weight reduction.
Here’s what we know about it.
Weight-loss drug in India
The market opportunity is huge in the world’s most populous country, which has high obesity rates, especially among women, and the second-highest number of people with type-2 diabetes globally. Indian drugmakers are testing their own versions of weight-loss drugs, while illegal versions are also sold online.
“Our famous Mounjaro – it’s under review now. So, perhaps as early as next year to the Indian market,” Ricks told Reuters on the sidelines of the BioAsia conference in the southern state of Telangana.
When asked about potentially partnering with others to bring the drug to the market, Ricks said the US drugmaker was “open to any way to reach more patients as long as it makes sense for the company and we can supply the market.”
Mounjaro, chemically known as tirzepatide, is currently sold in the United Kingdom and Europe under the same brand name for both conditions. However, it is sold under the brand name Zepbound for weight loss in the US.
Impact Shorts
View AllMounjaro is being reviewed by Indian drug regulators, for which Lilly is using data from its global trials, which included some Indian participants, a company source said, declining to be named as they are not authorised to speak to the media.
Rising demand for diabetes drug
Lilly’s Mounjaro and Zepbound as well as Danish rival Novo Nordisk’s in-demand Wegovy and Ozempic are therapies known as GLP-1 receptor agonists, developed to control blood sugar in patients with type 2 diabetes.
But they also slow digestion, helping patients feel full longer, which has led to an explosion in their popularity and left Lilly and Novo Nordisk struggling to keep up with demand.
The global market for these treatments is expected to reach at least $100 billion (Rs 8.28 lakh crore) by the end of the decade, analysts estimate.
Last year, a top Novo Nordisk official told Reuters the Danish company was aiming to bring Wegovy to India in 2026.
Indian drugmakers, which are among the world’s largest generic drug makers, are already developing their own versions of Wegovy.
These companies include Zydus Lifesciences, Sun Pharma, Cipla, Dr Reddy’s and Lupin.
Of them, Lupin and Cipla are Lilly’s Indian distributors, including for some of its older diabetes treatments such as Eglucent, Aplevant, Basaglar and Trulicity.
Regulatory rigmarole
India should boost patent protection, get rid of redundant policies and create a social safety net to win more investment from global drugmakers, Ricks said in his keynote address at the BioAsia conference.
These steps, he said, would help drive “broader interests for multinationals and foreign direct investment” in India’s pharmaceutical industry.
“India has many specific policies related to its regulatory environment all set up for good reason. But in hindsight, perhaps we can reflect upon them and find redundant policies that only cause delay and extra cost.”
Ricks said these regulatory challenges had the “two-way effect” of making it tough for companies like Lilly to bring new medicines into the market and constraining local biotechs to export their inventions.
With inputs from Reuters
 "'There's hope something is moving': Merz says Trump 'largely shares' Europe's position ahead of Alaska talks")
 "Alaska talks ‘a big win for Putin,’ John Bolton told Firstpost. Now Trump calls him ‘loser and dumb’")
 "US started this war, it dragged Ukraine into it, it should get out of it: Jeffrey Sachs")
 "Trump-Putin summit: Why Russia sold Alaska to the US in 1867")
 "'There's hope something is moving': Merz says Trump 'largely shares' Europe's position ahead of Alaska talks")
 "Alaska talks ‘a big win for Putin,’ John Bolton told Firstpost. Now Trump calls him ‘loser and dumb’")
 "US started this war, it dragged Ukraine into it, it should get out of it: Jeffrey Sachs")
 "Trump-Putin summit: Why Russia sold Alaska to the US in 1867")
